docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2022-21-5-25-30docru-187Research ArticleАКУШЕРСТВО И ПЕРИНАТОЛОГИЯOBSTETRICS AND PERINATOLOGYАльтернативные методы терапии рвоты беременныхAlternative Methods of Therapy of Nausea and Vomiting of Pregnant Womenhttps://orcid.org/0000-0002-2006-0110ЖелезоваМ. Е.ZhelezovaM. E.

Железова Мария Евгеньевна — д. м. н., профессор кафедры хирургии, акушерства и гинекологии Института фундаментальной медицины и биологии

420012, г. Казань, ул. Карла Маркса, д. 74

74 Karl Marks Str., Kazan, 420012

gelezovam@gmail.comhttps://orcid.org/0000-0002-9119-559XШариповаР. И.SharipovaR. I.

Шарипова Резеда Ильнуровна — к. м. н., доцент кафедры хирургии, акушерства и гинекологии Института фундаментальной медицины и биологии

420012, г. Казань, ул. Карла Маркса, д. 74

74 Karl Marks Str., Kazan, 420012

Rezedusha@mail.ruФГАОУ ВО «Казанский (Приволжский) федеральный университет»РоссияFederal State Educational Institution of Higher Education “Kazan (Volga region) Federal University”Russian Federation202217022025215ГИНЕКОЛОГИЯ2530Copyright © Железова М.Е., Шарипова Р.И., 20252025Железова М.Е., Шарипова Р.И.Zhelezova M.E., Sharipova R.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/187

Цель исследования: оценить эффективность применения экстракта имбиря в терапии токсикоза легкой и средней тяжести.Дизайн: наблюдательное (обсервационное) исследование.Материалы и методы. В исследование включены 56 беременных с симптомами токсикоза легкой и средней тяжести с жалобами на тошноту и/или рвоту при первом обращении на сроках 6–16 недель. Степень тяжести токсикоза оценивалась по шкале Pregnancy-Unique Quantification of Emesis and Nausea до начала терапии, на 4-е и 7-е сутки лечения. Беременные были разделены на две группы. Основную группу составили 28 женщин, принимавших биологически активную добавку Прегинор, группу сравнения — 28 пациенток, которым давали лишь рекомендации по модификации образа жизни и диеты. Из 56 исследуемых беременных 36 были с токсикозом легкой степени (18 женщин из основной группы и 18 в группе сравнения); у 20 беременных наблюдалось среднетяжелое течение токсикоза (10 пациенток из основной группы, 10 из группы сравнения). Прегинор содержит высокоселективный экстракт корня имбиря (67 мг), стандартизированный по содержанию гингеролов до 5%, что соответствует около 1 г свежего имбиря; витамин В6 1,4 мг, магния лактат 112,5 мг.Результаты. Купирование симптомов тошноты и рвоты при легком течении токсикоза у беременных, принимавших имбирь, произошло в среднем на 48 часов быстрее, чем у пациенток, получивших только рекомендации по модификации образа жизни и диеты: через 3,3 (0,5) и 5,1 (1,2) дня соответственно (t = –5,60, p = 0,000). При среднетяжелом течении токсикоза прием имбиря также способствовал облегчению состояния у большинства пациенток (80%).Заключение. Прегинор — эффективное нефармакологическое средство для купирования симптомов тошноты и рвоты при легком и среднетяжелом токсикозе беременных. Целесообразно рекомендовать Прегинор для широкого внедрения в клиническую практику, повышая информированность медицинского персонала и пациенток о его эффективности и безопасности.

Study Objective: Evaluation of the effectiveness of ginger extract in the treatment of nausea and vomiting light and moderate range of pregnant women.Study Design: Observational study.Materials and Methods. The research included 56 pregnant women with symptoms of nausea and vomiting: at the first visit they had complaints of nausea and/or vomiting being 6–16 weeks pregnant. The severity of nausea and vomiting was assessed on the Pregnancy-Unique Quantification of Emesis and Nausea scale before the start of therapy, on days 4 and 7 of treatment. The pregnant women were divided into two groups. The main group consisted of 28 women who took the dietary supplement Preginor, a comparison group — 28 patients who were given only recommendations for lifestyle and diet modification. Among 56 pregnant women who were studied, there 36 were with light symptoms of nausea and vomiting (18 women from the main group and 18 in the comparison group); 20 pregnant women had a moderate degree of nausea and vomiting (10 patients from the main group, 10 from the comparison group). Preginor contains a highly selective ginger root extract (67 mg) standardized to 5% gingerols, which corresponds to about 1 g of fresh ginger; vitamin B6 1.4 mg, magnesium lactate 112.5 mg.Study Results. Relief of symptoms of nausea and vomiting in pregnant women who took ginger was on average 48 hours faster compared to patients who received only recommendations for lifestyle and diet modification: after 3,3 (0,5) and 5,1 (1,2) days, respectively (t = –5,60, p = 0.000). With a moderate course of nausea and vomiting, taking ginger also helped to alleviate the condition in the majority of patients (80%).Conclusion. Preginor is an effective non-pharmacological remedy for the relief of symptoms of nausea and vomiting of pregnant women. It is advisable to recommend the dietary supplement Preginor for widespread introduction into clinical practice, raising the awareness of medical personnel and patients about its effectiveness and safety.

тошнота и рвота беременныхчрезмерная рвота беременныхэкстракт имбиряvomitingnauseahyperemesis gravidarumginger extractReferencesEinarson T.R., Piwko C., Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J. Popul. Ther. Clin. Pharmacol. 2013; 20(2): e171–83.Einarson T.R., Piwko C., Koren G. Quantifying the global rates of nausea and vomiting of pregnancy: a meta analysis. J. Popul. Ther. Clin. Pharmacol. 2013; 20(2): e171–83.Jansen L.A.W., Koot M.H., Van’t Hooft J., Dean C.R. et al. The windsor definition for hyperemesis gravidarum: a multistakeholder international consensus definition. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 266: 15–22. DOI: 10.1016/j.ejogrb.2021.09.004Jansen L.A.W., Koot M.H., Van’t Hooft J., Dean C.R. et al. The windsor definition for hyperemesis gravidarum: a multistakeholder international consensus definition. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021; 266: 15–22. DOI: 10.1016/j.ejogrb.2021.09.004Erdal H., Holst L., Heitmann K., Trovik J. Antiemetic treatment of hyperemesis gravidarum in 1,064 Norwegian women and the impact of European warning on metoclopramide: a retrospective cohort study 2002–2019. BMC Pregnancy Childbirth. 2022; 22(1): 464. DOI: 10.1186/s12884-022-04777-xErdal H., Holst L., Heitmann K., Trovik J. Antiemetic treatment of hyperemesis gravidarum in 1,064 Norwegian women and the impact of European warning on metoclopramide: a retrospective cohort study 2002–2019. BMC Pregnancy Childbirth. 2022; 22(1): 464. DOI: 10.1186/s12884-022-04777-xKoch K.L., Frissora C.L. Nausea and vomiting during pregnancy. Gastroenterol. Clin. North Am. 2003; 32(1): 201–34, vi. DOI: 10.1016/s0889-8553(02)00070-5Koch K.L., Frissora C.L. Nausea and vomiting during pregnancy. Gastroenterol. Clin. North Am. 2003; 32(1): 201–34, vi. DOI: 10.1016/s0889-8553(02)00070-5Lee N.M., Saha S. Nausea and vomiting of pregnancy. Gastroenterol. Clin. North Am. 2011; 40(2): 309–34, vii. DOI: 10.1016/j.gtc.2011.03.009Lee N.M., Saha S. Nausea and vomiting of pregnancy. Gastroenterol. Clin. North Am. 2011; 40(2): 309–34, vii. DOI: 10.1016/j.gtc.2011.03.009Fiaschi L., Nelson-Piercy C., Gibson J., Szatkowski L. et al. Adverse maternal and birth outcomes in women admitted to hospital for hyperemesis gravidarum: a population-based cohort study. Paediatr. Perinat. Epidemiol. 2018; 32(1): 40–51. DOI: 10.1111/ppe.12416Fiaschi L., Nelson-Piercy C., Gibson J., Szatkowski L. et al. Adverse maternal and birth outcomes in women admitted to hospital for hyperemesis gravidarum: a population-based cohort study. Paediatr. Perinat. Epidemiol. 2018; 32(1): 40–51. DOI: 10.1111/ppe.12416Fejzo M.S., Trovik J., Grooten I.J., Sridharan K. et al. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat. Rev. Dis. Primers. 2019; 5(1): 62. DOI: 10.1038/s41572-019-0110-3Fejzo M.S., Trovik J., Grooten I.J., Sridharan K. et al. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat. Rev. Dis. Primers. 2019; 5(1): 62. DOI: 10.1038/s41572-019-0110-3Nana M., Tydeman F., Bevan G., Boulding H. et al. Hyperemesis gravidarum is associated with increased rates of termination of pregnancy and suicidal ideation: results from a survey completed by > 5000 participants. Am. J. Obstet. Gynecol. 2021; 224(6): 629–31. DOI: 10.1016/j.ajog.2021.03.006Nana M., Tydeman F., Bevan G., Boulding H. et al. Hyperemesis gravidarum is associated with increased rates of termination of pregnancy and suicidal ideation: results from a survey completed by > 5000 participants. Am. J. Obstet. Gynecol. 2021; 224(6): 629–31. DOI: 10.1016/j.ajog.2021.03.006Dean C.R., Bruin C.M., O’Hara M.E., Roseboom T.J. et al. The chance of recurrence of hyperemesis gravidarum: a systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. X. 2020; 5: 100105. DOI: 10.1016/j.eurox.2019.100105Dean C.R., Bruin C.M., O’Hara M.E., Roseboom T.J. et al. The chance of recurrence of hyperemesis gravidarum: a systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. X. 2020; 5: 100105. DOI: 10.1016/j.eurox.2019.100105Nijsten K., Dean C., van der Minnen L.M., Bais J.M. et al. Recurrence, postponing pregnancy and termination rates after hyperemesis gravidarum: follow-up of the MOTHER study. Acta Obstet. Gynecol. Scand. 2021; 100(9): 1636–43. DOI: 10.1111/aogs.14197Nijsten K., Dean C., van der Minnen L.M., Bais J.M. et al. Recurrence, postponing pregnancy and termination rates after hyperemesis gravidarum: follow-up of the MOTHER study. Acta Obstet. Gynecol. Scand. 2021; 100(9): 1636–43. DOI: 10.1111/aogs.14197Bustos M., Venkataramanan R., Caritis S. Nausea and vomiting of pregnancy — what's new? Auton. Neurosci. 2017; 202: 62–72. DOI: 10.1016/j.autneu.2016.05.002Bustos M., Venkataramanan R., Caritis S. Nausea and vomiting of pregnancy — what's new? Auton. Neurosci. 2017; 202: 62–72. DOI: 10.1016/j.autneu.2016.05.002Zhang Y., Cantor R.M., MacGibbon K., Romero R. et al. Familial aggregation of hyperemesis gravidarum. Am. J. Obstet. Gynecol. 2011; 204(3): 230.e1–7. DOI: 10.1016/j.ajog.2010.09.018Zhang Y., Cantor R.M., MacGibbon K., Romero R. et al. Familial aggregation of hyperemesis gravidarum. Am. J. Obstet. Gynecol. 2011; 204(3): 230.e1–7. DOI: 10.1016/j.ajog.2010.09.018Niebyl J.R. Clinical practice. Nausea and vomiting in pregnancy. N. Engl. J. Med. 2010; 363(16): 1544–50. DOI: 10.1056/NEJMcp1003896Niebyl J.R. Clinical practice. Nausea and vomiting in pregnancy. N. Engl. J. Med. 2010; 363(16): 1544–50. DOI: 10.1056/NEJMcp1003896Goodwin T.M. Hyperemesis gravidarum. Obstet. Gynecol. Clin. North Am. 2008; 35(3): 401–17, viii. DOI: 10.1016/j.ogc.2008.04.002Goodwin T.M. Hyperemesis gravidarum. Obstet. Gynecol. Clin. North Am. 2008; 35(3): 401–17, viii. DOI: 10.1016/j.ogc.2008.04.002Golberg D., Szilagyi A., Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet. Gynecol. 2007; 110(3): 695–703. DOI: 10.1097/01.AOG.0000278571.93861.26Golberg D., Szilagyi A., Graves L. Hyperemesis gravidarum and Helicobacter pylori infection: a systematic review. Obstet. Gynecol. 2007; 110(3): 695–703. DOI: 10.1097/01.AOG.0000278571.93861.26Shaban M.M., Kandil H.O., Elshafei A.H. Helicobacter pylori seropositivity in patients with hyperemesis gravidarum. Am. J. Med. Sci. 2014; 347(2): 101–5. DOI: 10.1097/MAJ.0b013e31827bef91Shaban M.M., Kandil H.O., Elshafei A.H. Helicobacter pylori seropositivity in patients with hyperemesis gravidarum. Am. J. Med. Sci. 2014; 347(2): 101–5. DOI: 10.1097/MAJ.0b013e31827bef91Grooten I.J., Mol B.W., van der Post J.A.M., Ris-Stalpers C. et al. Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: the MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding). BMC Pregnancy Childbirth. 2016; 16: 22. DOI: 10.1186/s12884-016-0815-1Grooten I.J., Mol B.W., van der Post J.A.M., Ris-Stalpers C. et al. Early nasogastric tube feeding in optimising treatment for hyperemesis gravidarum: the MOTHER randomised controlled trial (Maternal and Offspring outcomes after Treatment of HyperEmesis by Refeeding). BMC Pregnancy Childbirth. 2016; 16: 22. DOI: 10.1186/s12884-016-0815-1Bischoff S.C., Renzer C. Nausea and nutrition. Auton. Neurosci. 2006; 129(1–2): 22–7. DOI: 10.1016/j.autneu.2006.07.011Bischoff S.C., Renzer C. Nausea and nutrition. Auton. Neurosci. 2006; 129(1–2): 22–7. DOI: 10.1016/j.autneu.2006.07.011Jueckstock J.K., Kaestner R., Mylonas I. Managing hyperemesis gravidarum: a multimodal challenge. BMC Med. 2010; 8: 46. DOI: 10.1186/1741-7015-8-46Jueckstock J.K., Kaestner R., Mylonas I. Managing hyperemesis gravidarum: a multimodal challenge. BMC Med. 2010; 8: 46. DOI: 10.1186/1741-7015-8-46Sechi G., Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007; 6(5): 442–55. DOI: 10.1016/S1474-4422(07)70104-7Sechi G., Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007; 6(5): 442–55. DOI: 10.1016/S1474-4422(07)70104-7Chiossi G., Neri I., Cavazzuti M., Basso G. et al. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet. Gynecol. Surv. 2006; 61(4): 255–68. DOI: 10.1097/01.ogx.0000206336.08794.65Chiossi G., Neri I., Cavazzuti M., Basso G. et al. Hyperemesis gravidarum complicated by Wernicke encephalopathy: background, case report, and review of the literature. Obstet. Gynecol. Surv. 2006; 61(4): 255–68. DOI: 10.1097/01.ogx.0000206336.08794.65Berdai M.A., Labib S., Harandou M. Wernicke's encephalopathy complicating hyperemesis during pregnancy. Case Rep. Crit. Care. 2016; 2016: 8783932. DOI: 10.1155/2016/8783932Berdai M.A., Labib S., Harandou M. Wernicke's encephalopathy complicating hyperemesis during pregnancy. Case Rep. Crit. Care. 2016; 2016: 8783932. DOI: 10.1155/2016/8783932American College of Obstetrics and Gynecology. ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy. Obstet. Gynecol. 2004; 103(4): 803–14.American College of Obstetrics and Gynecology. ACOG (American College of Obstetrics and Gynecology) Practice Bulletin: nausea and vomiting of pregnancy. Obstet. Gynecol. 2004; 103(4): 803–14.Viljoen E., Visser J., Koen N., Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr. J. 2014; 13: 20. DOI: 10.1186/1475-2891-13-20Viljoen E., Visser J., Koen N., Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr. J. 2014; 13: 20. DOI: 10.1186/1475-2891-13-20Haniadka R., Saldanha E., Sunita V., Palatty P.L. et al. A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe). Food Funct. 2013; 4(6): 845–55. DOI: 10.1039/c3fo30337cHaniadka R., Saldanha E., Sunita V., Palatty P.L. et al. A review of the gastroprotective effects of ginger (Zingiber officinale Roscoe). Food Funct. 2013; 4(6): 845–55. DOI: 10.1039/c3fo30337cHu M.L., Rayner C.K., Wu K.L., Chuah S.K. et al. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J. Gastroenterol. 2011; 17(1): 105–10. DOI: 10.3748/wjg.v17.i1.105Hu M.L., Rayner C.K., Wu K.L., Chuah S.K. et al. Effect of ginger on gastric motility and symptoms of functional dyspepsia. World J. Gastroenterol. 2011; 17(1): 105–10. DOI: 10.3748/wjg.v17.i1.105Pertz H.H., Lehmann J., Roth-Ehrang R., Elz S. Effects of ginger constituents on the gastrointestinal tract: role of cholinergic M3 and serotonergic 5-HT3 and 5-HT4 receptors. Planta Med. 2011; 77(10): 973–8. DOI: 10.1055/s-0030-1270747Pertz H.H., Lehmann J., Roth-Ehrang R., Elz S. Effects of ginger constituents on the gastrointestinal tract: role of cholinergic M3 and serotonergic 5-HT3 and 5-HT4 receptors. Planta Med. 2011; 77(10): 973–8. DOI: 10.1055/s-0030-1270747Vutyavanich T., Kraisarin T., Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. Obstet. Gynecol. 2001; 97(4): 577–82. DOI: 10.1016/s0029-7844(00)01228-xVutyavanich T., Kraisarin T., Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. Obstet. Gynecol. 2001; 97(4): 577–82. DOI: 10.1016/s0029-7844(00)01228-xPortnoi G., Chng L.A., Karimi-Tabesh L., Koren G. et al. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am. J. Obstet. Gynecol. 2003; 189(5): 1374–7. DOI: 10.1067/s0002-9378(03)00649-5Portnoi G., Chng L.A., Karimi-Tabesh L., Koren G. et al. Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Am. J. Obstet. Gynecol. 2003; 189(5): 1374–7. DOI: 10.1067/s0002-9378(03)00649-5Stanisiere J., Mousset P.Y., Lafay S. How safe is ginger rhizome for decreasing nausea and vomiting in women during early pregnancy? Foods. 2018; 7(4): 50. DOI: 10.3390/foods7040050Stanisiere J., Mousset P.Y., Lafay S. How safe is ginger rhizome for decreasing nausea and vomiting in women during early pregnancy? Foods. 2018; 7(4): 50. DOI: 10.3390/foods7040050Gilboa S.M., Ailes E.C., Rai R.P., Anderson J.A. et al. Antihistamines and birth defects: a systematic review of the literature. Expert Opin. Drug Saf. 2014; 13(12): 1667–98. DOI: 10.1517/14740338.2014.970164Gilboa S.M., Ailes E.C., Rai R.P., Anderson J.A. et al. Antihistamines and birth defects: a systematic review of the literature. Expert Opin. Drug Saf. 2014; 13(12): 1667–98. DOI: 10.1517/14740338.2014.970164Tan P.C., Khine P.P., Vallikkannu N., Omar S.Z. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet. Gynecol. 2010; 115(5): 975–81. DOI: 10.1097/AOG.0b013e3181d99290Tan P.C., Khine P.P., Vallikkannu N., Omar S.Z. Promethazine compared with metoclopramide for hyperemesis gravidarum: a randomized controlled trial. Obstet. Gynecol. 2010; 115(5): 975–81. DOI: 10.1097/AOG.0b013e3181d99290Matok I., Gorodischer R., Koren G., Sheiner E. et al. The safety of metoclopramide use in the first trimester of pregnancy. N. Engl. J. Med. 2009; 360(24): 2528–35. DOI: 10.1056/NEJMoa0807154Matok I., Gorodischer R., Koren G., Sheiner E. et al. The safety of metoclopramide use in the first trimester of pregnancy. N. Engl. J. Med. 2009; 360(24): 2528–35. DOI: 10.1056/NEJMoa0807154Sanu O., Lamont R.F. Hyperemesis gravidarum: pathogenesis and the use of antiemetic agents. Expert Opin. Pharmacother. 2011; 12(5): 737–48. DOI: 10.1517/14656566.2010.537655Sanu O., Lamont R.F. Hyperemesis gravidarum: pathogenesis and the use of antiemetic agents. Expert Opin. Pharmacother. 2011; 12(5): 737–48. DOI: 10.1517/14656566.2010.537655Badell M.L., Ramin S.M., Smith J.A. Treatment options for nausea and vomiting during pregnancy. Pharmacotherapy. 2006; 26(9): 1273–87. DOI: 10.1592/phco.26.9.1273Badell M.L., Ramin S.M., Smith J.A. Treatment options for nausea and vomiting during pregnancy. Pharmacotherapy. 2006; 26(9): 1273–87. DOI: 10.1592/phco.26.9.1273Einarson A., Maltepe C., Navioz Y., Kennedy D. et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG. 2004; 111(9): 940–3. DOI: 10.1111/j.1471-0528.2004.00236.xEinarson A., Maltepe C., Navioz Y., Kennedy D. et al. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. BJOG. 2004; 111(9): 940–3. DOI: 10.1111/j.1471-0528.2004.00236.xPasternak B., Svanström H., Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N. Engl. J. Med. 2013; 368(9): 814–23. DOI: 10.1056/NEJMoa1211035Pasternak B., Svanström H., Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N. Engl. J. Med. 2013; 368(9): 814–23. DOI: 10.1056/NEJMoa1211035Carstairs S.D. Ondansetron use in pregnancy and birth defects: a systematic review. Obstet. Gynecol. 2016; 127(5): 878–83. DOI: 10.1097/AOG.0000000000001388Carstairs S.D. Ondansetron use in pregnancy and birth defects: a systematic review. Obstet. Gynecol. 2016; 127(5): 878–83. DOI: 10.1097/AOG.0000000000001388Danielsson B., Wikner B.N., Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod. Toxicol. 2014; 50: 134–7. DOI: 10.1016/j.reprotox.2014.10.017Danielsson B., Wikner B.N., Källén B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod. Toxicol. 2014; 50: 134–7. DOI: 10.1016/j.reprotox.2014.10.017Law R., Maltepe C., Bozzo P., Einarson A. Treatment of heartburn and acid reflux associated with nausea and vomiting during pregnancy. Can. Fam. Physician. 2010; 56(2): 143–4.Law R., Maltepe C., Bozzo P., Einarson A. Treatment of heartburn and acid reflux associated with nausea and vomiting during pregnancy. Can. Fam. Physician. 2010; 56(2): 143–4.Gill S.K., Maltepe C., Koren G. The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. Can. J. Gastroenterol. 2009; 23(4): 270–2. DOI: 10.1155/2009/678514Gill S.K., Maltepe C., Koren G. The effect of heartburn and acid reflux on the severity of nausea and vomiting of pregnancy. Can. J. Gastroenterol. 2009; 23(4): 270–2. DOI: 10.1155/2009/678514Zielinski R., Searing K., Deibel M. Gastrointestinal distress in pregnancy: prevalence, assessment, and treatment of 5 common minor discomforts. J. Perinat. Neonatal Nurs. 2015; 29(1): 23–31. DOI: 10.1097/JPN.0000000000000078Zielinski R., Searing K., Deibel M. Gastrointestinal distress in pregnancy: prevalence, assessment, and treatment of 5 common minor discomforts. J. Perinat. Neonatal Nurs. 2015; 29(1): 23–31. DOI: 10.1097/JPN.0000000000000078Nelson-Piercy C., Fayers P., de Swiet M. Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum. BJOG. 2001; 108(1): 9–15. DOI: 10.1111/j.1471-0528.2001.00017.xNelson-Piercy C., Fayers P., de Swiet M. Randomised, double-blind, placebo-controlled trial of corticosteroids for the treatment of hyperemesis gravidarum. BJOG. 2001; 108(1): 9–15. DOI: 10.1111/j.1471-0528.2001.00017.xPark-Wyllie L., Mazzotta P., Pastuszak A., Moretti M.E. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62(6): 385–92. DOI: 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-ZPark-Wyllie L., Mazzotta P., Pastuszak A., Moretti M.E. et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000; 62(6): 385–92. DOI: 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-ZPradat P., Robert-Gnansia E., Di Tanna G.L., Rosano A. et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res. A Clin. Mol. Teratol. 2003; 67(12): 968–70. DOI: 10.1002/bdra.10134Pradat P., Robert-Gnansia E., Di Tanna G.L., Rosano A. et al. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res. A Clin. Mol. Teratol. 2003; 67(12): 968–70. DOI: 10.1002/bdra.10134Skuladottir H., Wilcox A.J., Ma C., Lammer E.J. et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res. A Clin. Mol. Teratol. 2014; 100(6): 499–506. DOI: 10.1002/bdra.23248Skuladottir H., Wilcox A.J., Ma C., Lammer E.J. et al. Corticosteroid use and risk of orofacial clefts. Birth Defects Res. A Clin. Mol. Teratol. 2014; 100(6): 499–506. DOI: 10.1002/bdra.23248Parker S., Star J., Collet B., Speltz M.L. et al. Nausea and vomiting and neurodevelopment outcomes in offspring. J. Pediatr. Perinat. Epidemiol. 2014; 28(6): 527–35. DOI: 10.1111/ppe.12151Parker S., Star J., Collet B., Speltz M.L. et al. Nausea and vomiting and neurodevelopment outcomes in offspring. J. Pediatr. Perinat. Epidemiol. 2014; 28(6): 527–35. DOI: 10.1111/ppe.12151

The authors declare that there are no conflicts of interest present.